Humana (HUM) to Release Quarterly Earnings on Wednesday
Humana (NYSE:HUM) will be announcing its earnings results before the market opens on Wednesday, February 7th. Analysts expect the company to announce earnings of $2.02 per share for the quarter.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. Humana’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.18 EPS. On average, analysts expect Humana to post $12 EPS for the current fiscal year and $13 EPS for the next fiscal year.
Humana (NYSE:HUM) opened at $276.50 on Monday. The firm has a market capitalization of $39,500.79, a P/E ratio of 21.75, a price-to-earnings-growth ratio of 1.70 and a beta of 0.93. Humana has a fifty-two week low of $189.01 and a fifty-two week high of $293.35. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61.
A number of equities analysts have weighed in on HUM shares. Credit Suisse Group decreased their price target on Humana from $256.00 to $246.00 and set a “neutral” rating for the company in a report on Friday, November 10th. ValuEngine cut Humana from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Jefferies Group restated a “hold” rating and issued a $257.00 price target on shares of Humana in a report on Friday, October 13th. BMO Capital Markets upped their price target on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a report on Friday, November 10th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $242.00 price target (down previously from $245.00) on shares of Humana in a report on Thursday, November 9th. Nine research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $262.74.
In related news, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the sale, the vice president now directly owns 11,557 shares of the company’s stock, valued at approximately $2,843,484.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Brian P. Leclaire sold 1,679 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total value of $412,983.63. Following the sale, the senior vice president now directly owns 9,888 shares in the company, valued at $2,432,151.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,115 shares of company stock worth $2,501,627. Corporate insiders own 0.80% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.